Compare Stocks: ABOS, VSTM, NVCT, and IRWD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.31 -12.8%	$2.63	$1.24 ▼ $3.60	$167.06M	0.37	566,724 shs	467,834 shs
IRWD Ironwood Pharmaceuticals	$4.27 -5.7%	$4.14	$1.26 ▼ $5.78	$705.58M	0.2	3.06 million shs	1.66 million shs
NVCT Nuvectis Pharma	$21.01 -8.7%	$21.56	$5.55 ▼ $29.27	$685.77M	-0.26	172,904 shs	169,189 shs
VSTM Verastem	$8.18 -2.3%	$6.90	$3.43 ▼ $10.82	$740.78M	0.32	2.25 million shs	1.94 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+2.32%	-8.30%	-16.14%	+14.72%	+107.03%
IRWD Ironwood Pharmaceuticals	+2.72%	+11.58%	+5.59%	+15.86%	+214.58%
NVCT Nuvectis Pharma	+4.64%	+4.93%	-2.38%	-6.05%	+257.70%
VSTM Verastem	+4.76%	+14.03%	+21.48%	+117.40%	-8.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$2.31 -12.8%	$2.63	$1.24 ▼ $3.60	$167.06M	0.37	566,724 shs	467,834 shs
IRWD Ironwood Pharmaceuticals	$4.27 -5.7%	$4.14	$1.26 ▼ $5.78	$705.58M	0.2	3.06 million shs	1.66 million shs
NVCT Nuvectis Pharma	$21.01 -8.7%	$21.56	$5.55 ▼ $29.27	$685.77M	-0.26	172,904 shs	169,189 shs
VSTM Verastem	$8.18 -2.3%	$6.90	$3.43 ▼ $10.82	$740.78M	0.32	2.25 million shs	1.94 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	+2.32%	-8.30%	-16.14%	+14.72%	+107.03%
IRWD Ironwood Pharmaceuticals	+2.72%	+11.58%	+5.59%	+15.86%	+214.58%
NVCT Nuvectis Pharma	+4.64%	+4.93%	-2.38%	-6.05%	+257.70%
VSTM Verastem	+4.76%	+14.03%	+21.48%	+117.40%	-8.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	2.60	Moderate Buy	$7.00	203.03% Upside
IRWD Ironwood Pharmaceuticals	2.57	Moderate Buy	$6.23	45.98% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	72.54% Upside
VSTM Verastem	2.82	Moderate Buy	$13.83	69.11% Upside

Current Analyst Ratings Breakdown

Latest ABOS, VSTM, NVCT, and IRWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/17/2026	ABOS Acumen Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/17/2026	VSTM Verastem	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
9/16/2026	ABOS Acumen Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
9/15/2026	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$4.00 ➝ $5.00
9/11/2026	VSTM Verastem	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/11/2026	VSTM Verastem	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$18.00
9/4/2026	IRWD Ironwood Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
9/4/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	VSTM Verastem	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	NVCT Nuvectis Pharma	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$40.00

(Data available from 9/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.16 per share	N/A
IRWD Ironwood Pharmaceuticals	$296.15M	2.38	$0.25 per share	17.13	($1.61) per share	-2.65
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
VSTM Verastem	$30.91M	23.97	N/A	N/A	$0.74 per share	11.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$121.33M	-$1.63	N/A	N/A	N/A	N/A	-136.27%	-81.64%	11/11/2026 (Estimated)
IRWD Ironwood Pharmaceuticals	$24.02M	$0.77	5.55	N/A	N/A	33.36%	-58.38%	34.93%	11/9/2026 (Estimated)
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
VSTM Verastem	-$209.47M	-$2.66	N/A	N/A	N/A	-231.59%	-467.49%	-94.54%	11/3/2026 (Estimated)

Latest ABOS, VSTM, NVCT, and IRWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ABOS Acumen Pharmaceuticals	-$0.3593	-$0.45	-$0.0907	-$0.45	N/A	N/A
8/6/2026	Q2 2026	IRWD Ironwood Pharmaceuticals	$0.32	$0.31	-$0.01	$0.31	$114.84 million	$113.04 million
8/6/2026	Q2 2026	VSTM Verastem	-$0.4305	-$0.35	+$0.0805	-$0.35	$22.88 million	$40.08 million
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
VSTM Verastem	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.21	2.47	2.47
IRWD Ironwood Pharmaceuticals	N/A	6.06	6.06
NVCT Nuvectis Pharma	N/A	1.68	1.68
VSTM Verastem	1.48	2.25	2.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
IRWD Ironwood Pharmaceuticals	N/A
NVCT Nuvectis Pharma	96.77%
VSTM Verastem	88.37%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	10.20%
IRWD Ironwood Pharmaceuticals	9.30%
NVCT Nuvectis Pharma	28.55%
VSTM Verastem	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	61	72.32 million	64.94 million	Optionable
IRWD Ironwood Pharmaceuticals	100	165.24 million	149.87 million	Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
VSTM Verastem	102	90.56 million	88.81 million	Optionable

ABOS, VSTM, NVCT, and IRWD Headlines

Recent News About These Companies

Verastem (NASDAQ:VSTM) Shares Up 7.1% - Still a Buy?

September 22 at 11:19 AM | marketbeat.com

Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright

September 21 at 11:01 PM | marketbeat.com

Verastem, Inc. (NASDAQ:VSTM) Given Average Recommendation of "Moderate Buy" by Analysts

September 21 at 2:28 AM | americanbankingnews.com

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages

September 21 at 2:28 AM | marketbeat.com

Verastem's Shares Not Fully Valuing its Growth Potential, RBC Says

September 19, 2026 | finance.yahoo.com

Wolfe Research Begins Coverage on Verastem (NASDAQ:VSTM)

September 19, 2026 | americanbankingnews.com

Wall Street Zen Downgrades Verastem (NASDAQ:VSTM) to Sell

September 19, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Downgraded by Wall Street Zen to "Sell"

September 19, 2026 | marketbeat.com

RBC Capital Keeps Their Buy Rating on Verastem (VSTM)

September 18, 2026 | theglobeandmail.com

Verastem (NASDAQ:VSTM) Coverage Initiated by Analysts at Wolfe Research

September 17, 2026 | marketbeat.com

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

September 14, 2026 | streetinsider.com

Verastem (NASDAQ:VSTM) Earns Buy Rating from BTIG Research

September 13, 2026 | americanbankingnews.com

Verastem (NASDAQ:VSTM) Earns "Buy" Rating from HC Wainwright

September 13, 2026 | americanbankingnews.com

Bank of New York Mellon Corp Makes New Investment in Verastem, Inc. $VSTM

September 12, 2026 | marketbeat.com

Verastem's (VSTM) "Buy" Rating Reiterated at HC Wainwright

September 11, 2026 | marketbeat.com

Verastem: Avutometinib Plus Defactinib Data De-Risk Efficacy Thesis; Buy Rating Reiterated With Unchanged $18 Price Target

September 11, 2026 | tipranks.com

BTIG Research Reaffirms "Buy" Rating for Verastem (NASDAQ:VSTM)

September 11, 2026 | marketbeat.com

Opaleye Management Inc. Purchases New Position in Verastem, Inc. $VSTM

September 11, 2026 | marketbeat.com

Verastem Stock Skyrockets 121% in 3 Months: Here Is Why

September 8, 2026 | zacks.com

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers

September 8, 2026 | businesswire.com

Verastem (NASDAQ:VSTM) Stock Rating Upgraded by Wall Street Zen

September 5, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, VSTM, NVCT, and IRWD Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$2.31 -0.34 (-12.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.37 +0.06 (+2.38%)

As of 04:45 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.27 -0.26 (-5.74%)

Closing price 04:00 PM Eastern

Extended Trading

$4.30 +0.03 (+0.70%)

As of 05:24 PM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Nuvectis Pharma NASDAQ:NVCT

$21.01 -1.99 (-8.65%)

Closing price 04:00 PM Eastern

Extended Trading

$21.12 +0.10 (+0.50%)

As of 04:40 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Verastem NASDAQ:VSTM

$8.18 -0.19 (-2.27%)

Closing price 04:00 PM Eastern

Extended Trading

$8.15 -0.03 (-0.37%)

As of 04:51 PM Eastern

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABOS, VSTM, NVCT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABOS, VSTM, NVCT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABOS, VSTM, NVCT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, VSTM, NVCT, and IRWD Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Ironwood Pharmaceuticals NASDAQ:IRWD

Nuvectis Pharma NASDAQ:NVCT

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABOS, VSTM, NVCT, and IRWD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABOS, VSTM, NVCT, and IRWD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABOS, VSTM, NVCT, and IRWD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, VSTM, NVCT, and IRWD Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

Ironwood Pharmaceuticals NASDAQ:IRWD

Nuvectis Pharma NASDAQ:NVCT

Verastem NASDAQ:VSTM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools